
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Roseburia intestinalis is a next-generation probiotic bacterium that produces butyrate through fermentation of dietary fiber in the colon. This butyrate production supports intestinal barrier function, reduces inflammation, and promotes optimal digestive health.

Reported Benefits (Provisional)
Origin & History

Roseburia intestinalis is a gram-positive, anaerobic bacterium prevalent in the human gut. It is cultured under anaerobic conditions due to its oxygen sensitivity, often isolated from fecal samples for research purposes.
Research Narrative (Provisional)
Research on Roseburia intestinalis includes in vitro studies and animal models, with growing interest in its role in gut health and metabolic regulation. Human trials are limited but promising.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Produces butyrate and other short-chain fatty acids. - Contains enzymes that degrade complex carbohydrates. - Rich in polysaccharides beneficial for gut health.
Reported Mechanism (Provisional)
Roseburia intestinalis ferments complex carbohydrates and resistant starches through butyrate-CoA transferase pathways, producing short-chain fatty acids, particularly butyrate. Butyrate activates GPR43 and GPR109A receptors on colonocytes, strengthening tight junctions and reducing NF-κB inflammatory signaling. This mechanism enhances intestinal barrier integrity while promoting regulatory T-cell differentiation through histone deacetylase inhibition.
Clinical Narrative (Provisional)
Research on Roseburia intestinalis primarily consists of observational studies and in vitro experiments rather than randomized controlled trials. Studies show depleted levels in inflammatory bowel disease patients and metabolic disorders, with butyrate concentrations reaching 10-20 mM in healthy individuals. Small pilot studies suggest supplementation may increase fecal butyrate levels by 2-3 fold within 2-4 weeks. Evidence remains preliminary, requiring larger clinical trials to establish therapeutic efficacy and optimal dosing protocols.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







